HER2-positive breast cancer accounts for approximately 25-30% of all breast cancer cases, and carries a bad prognosis compared to HER2-negative breast cancer. Despite recent advances with the development of HER2-targeted treatments, mainly trastuzuma...

Grundlagenforschung - 01.01.2013 - 31.12.2014

Automatisch geschlossen

Mitarbeiter/innen: Driessen Christoph, Gibbons-Marsico Jennifer, Kraus Marianne